Bovine respiratory syncytial virus antigen protein

Abstract

The invention discloses bovine respiratory syncytial virus antigen protein. Compared with SEQ AAB28458.1, an amino acid sequence of the bovine respiratory syncytial virus antigen protein is characterized in that at least two sites are replaced by cysteines, the replaced cysteines are in disulfide linkage, and improvements such as disulfide linkage, hole filling and single-strand ligation on this basis. The invention further provides a method for preparing the bovine respiratory syncytial virus antigen protein. The bovine respiratory syncytial virus antigen protein and the method for preparing the same have the advantages that technologies and theories of protein crystallography are applied, structural changes of protein in a virus infection and pathopoiesis process are determined, and the key viral protein is subjected to genetic engineering modifications according to structural change results so as to become the antigen protein which is infectious but not pathogenic and capable of causing high-efficiency reaction of animal antigens; the bovine respiratory syncytial virus antigen protein is capable of effectively preventing and treating bovine respiratory syncytial virus infection and is developed into satisfactory viral vaccines on the basis to control and prevent loss brought by virus infection, thereby being of great economic and social significance.

Description

technical field [0001] The invention belongs to the technical field of biological product preparation, and relates to a bovine respiratory syncytial virus antigen protein and a preparation method thereof. Background technique [0002] Bovine Respiration Syncytial Virus (BRSV) infection can cause bovine respiratory diseases, and is listed as an important bovine disease in European Community countries after bovine mucosal disease (BVD) and bovine infectious rhinotracheitis (IBR). one of the diseases. The disease is prevalent worldwide, and its harmfulness is that the incidence of BRSV infection reaches as high as 60%-80%, and the mortality rate reaches more than 20% in some outbreaks, causing great economic losses to the cattle industry. Although this BRSV has been included in the research and development category since the 1970s, ideal drugs and vaccines have not been developed due to various reasons. Although there have been reports on various inactivated, attenuated, reco...

AI Technical Summary

Problems solved by technology

With the continuous advancement of human knowledge, the limitations of traditional vaccines are increasingly revealed: (1) animal and human viruses need to be cultured in animal cells, which makes the cost of vaccine production very high; (2) pathogenic viruses in vaccines The substance may not be completely killed or sufficiently attenuated during the vaccine production process, which will cause the vaccine to contain highly toxic pathogenic substances, which in turn will cause the disease to spread in a wider range; (3) Attenuated strains may occur mutation, disease-causing

Images